Although DPP4i has shown many anti-inflammatory effects in diabetes complications and other disease, this effect has not been shown in clinical trials
Oncotarget 4(6):890-8, 2013
So far, several unimolecular dual and triple agonists are in clinical evaluation and as of today, the improved metabolic efficacy does not seem to be compromised by reduced safety [25].
doi: 10.3389/fphar.2021.628651 Received 12 November 2020 Accepted 19 March 2021 Published 26 April 2021 Volume 12 - 2021 Edited by Akhilesh K Pandey, Texas Tech University Health Sciences Center, United States Reviewed by Shashank Kumar, Central University of Punjab, India Vasavi Gorantla, St.Georges University School of Medicine, Grenada Haripriya Vittal Rao, Wake Forest Baptist Medical Center, United States Tulika Mishra, Deen Dayal Upadhyay Gorakhpur University, India Updates Copyright 2021 Liu, Yang, Zhao, Tang, Duan, Zhou, Chen, Sun, Song, Hu and Shi
Opera_id_244 73
Type: Tetrapeptide